Target intelligence / Profile preview

G protein-coupled receptor 3 (GPR3)

Target
GPR3
Molecular classification
G protein-coupled receptor, Receptor, Orphan receptor, Class A (rhodopsin-like) GPCR
01

Overview

G protein-coupled receptor 3 (GPR3) is an orphan class A GPCR broadly expressed in the brain (hypothalamus, hippocampus, cortex) and peripheral tissues (liver, ovary)[1][5]. It is notable for its high constitutive activity, meaning it activates Gs proteins and elevates cAMP in the absence of a classical ligand. This intrinsic activity regulates diverse physiological functions, including neuronal growth, oocyte maturation, and adipose tissue thermogenesis[1][6][2]. GPR3 is implicated in Alzheimer’s disease, as it regulates γ-secretase activity and amyloid precursor protein processing, and is also involved in oocyte meiosis arrest and cold-induced adipose lipolysis[1][3][6]. Structural studies reveal a lipid-like molecule, possibly an endogenous lipid or fatty acid, binds within its hydrophobic orthosteric pocket, suggesting activation via a ubiquitous lipid ligand, although the precise endogenous ligand is still debated[1][5]. GPR3 operates via a constitutive coupling to Gs, driving cAMP signaling, and exhibits structural features typical of lipid-responsive GPCRs, including a dynamic hydrophobic tunnel[1][5]. No approved drugs target GPR3 clinically; however, inverse agonists and other tool compounds are under investigation as potential modulators for diseases such as Alzheimer’s disease[1][5].

Other names
ACCAGPR3ACCA orphan receptoradenylate cyclase constitutive activator
02

Mechanism of action

Constitutive activation of Gs protein, leading to increased adenylate cyclase activity and cAMP production[1][3][5] Inverse agonists reduce basal activity by stabilizing the inactive receptor conformation[1]

03

Biological functions

Signal transductionRegulation of cyclic AMP (cAMP) levelsNeuronal development (neurite outgrowth/proliferation/survival)Oocyte maturationThermogenesis
04

Disease associations

Neurodegenerative disease (Alzheimer’s disease)Reproductive disorders (premature ovarian failure)Metabolic disorders (implicated in adipose tissue thermogenesis)
05

Safety considerations

Noted challenges include high constitutive activity and orphan receptor status (uncertain endogenous ligand), which complicate selective drug targeting and may risk off-target effects[1][3][5]
06

Interacting drugs

AF64394 (reported inverse agonist in structural studies[1])

1 more in the full profile.

07

Biomarkers

None established for diagnostic or therapeutic monitoring

Beyond the preview

Go deeper on G protein-coupled receptor 3 (GPR3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G protein-coupled receptor 3 (GPR3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call